Digital Obesity Care Reaches Socioeconomically Diverse Patients
In a real-world cohort of over 40,000 people living with obesity, digital care engaged patients across all socioeconomic groups, including low- and middle-income populations. However, affordability emerged as the primary driver of treatment discontinuation, with economic barriers disproportionately limiting long-term access and continuity of care.
Real-World Outcomes of Tirzepatide and Semaglutide in 40,000+ Patients
Sustained Real-World Weight Loss in 40,000+ Patients
Substantial weight loss was achieved with GLP-1–based pharmacotherapy within a comprehensive digital obesity care model. Outcomes were maintained up to 24 months, with 57% of patients still in treatment, demonstrating strong long-term effectiveness in real-world care.
High-Volume Patient–Caregiver Interactions in a Fully Digital Obesity Care Model
This real-world analysis quantifies patient–caregiver interactions in a fully digital obesity care model with unlimited follow-up.
Summary
Across 156 weeks, 7.7 million messages were exchanged between 50.414 patients and a multidisciplinary team (mean 5.5 per patient/week), and 2.3 million weight entries were logged, highlighting how a fully digital care pathway enables continuous patient engagement and sustained self-monitoring over time.
Testosterone, Obesity and Men's Health: Role, Health Impact, and Treatment Options
Obesity significantly impacts men’s hormonal health — particularly testosterone — increasing risks of fatigue, weight gain, and chronic disease; understanding this connection is key to effective treatment and long-term wellbeing.
Understanding the Far-Reaching Risks of Obesity in Men: A Comprehensive Overview
Obesity in men is more than a weight issue — it’s a complex medical condition with far-reaching health risks. From heart disease and liver problems to hormonal and psychological effects, understanding these connections is key to effective prevention and management.



.webp)

.webp)




